How Glympse Bio oversubscribed their Series B funding amidst the pandemic
Release Date:
In this episode of Conversations in Healthcare, Mike Ward, Global Head of Thought Leadership at DRG, part of Clarivate, speaks with Dr. Caroline Loew, President and CEO from Glympse Bio. They discuss the biotech’s focus on both disease detection and response to treatment using bioengineered sensors, starting with NASH. Dr. Loew also shares career advice for moving from pharma to biotech and how she pivoted the company’s narrative during a funding round at the bottom of the pandemic-related stock market crash. Hosted on Acast. See acast.com/privacy for more information.
How Glympse Bio oversubscribed their Series B funding amidst the pandemic